Intrahepatic cholestasis of pregnancy is the most common liver disorder in pregnancy that adversely affects maternal well being and fetal outcome. We present a case of eclampsia that followed intrahepatic cholestasis of pregnancy in a patient who has a sister with the same history in her two former pregnancies despite being treated with ursodeoxycholic acid. Intrahepatic cholestasis and pregnancy is briefly reviewed based on a unique case report presenting with intrahepatic cholestasis complicated by eclampsia.

Being one of the most performed invasive techniques for prenatal diagnose, second-trimester genetic amniocentesis is a reliable and safe method. Although the size of this study is limited, our complication rates are similar to the related literature.

Growing rates of osteoporosis in the whole world is a serious health problem. As the "expected lifetime" is prolonged, population of elderly women with chronic diseases who require long-term treatment increases. This study aimed to compare antiresorptive treatment-that has become a classic treatment in the light of Canadian Guideline for osteoporosis-with the antiresorptive plus osteoblastic activity inducing treatment modality. The clinical and laboratory results of patients treated with a single dose of 2 mg Strontium ranelate sachet (Protelos ®) or alendronate sodium used weekly 70 mg tablet (Fosamax ® once a week tablet) for 12-months were compared. Treatment compliance has been questioned. A hundred women in post-menopausal period were included in this study. Patient satisfaction survey among the group of strontium ranelate was unsatisfactory. Among patients using alendronate sodium the ease of use in this sense obtained a rate of 91% satisfaction from patients.

No abstract